Evidence map›Paper›PMID 39838661›Full record

ReviewCurrent pharmaceutical biotechnology2026

Nanoparticles as Delivery Vehicles for Vaccines: The Use of Gold Nanoparticles.

Nadeem Kizilbash, Nida Suhail, Mohamed Soliman, Ranya Mohammed Elmagzoub, Madison Marsh, Rimsha Farooq

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nadeem KizilbashDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Northern Border University, Arar, 91431, Saudi Arabia.ORCID 0000-0003-4498-9343
Nida SuhailDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Northern Border University, Arar, 91431, Saudi Arabia.ORCID 0000-0003-1314-5041
Mohamed SolimanDepartment of Microbiology, Faculty of Medicine, Northern Border University, Arar, 91431, Saudi Arabia.
Ranya Mohammed ElmagzoubDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Northern Border University, Arar, 91431, Saudi Arabia.ORCID 0009-0006-4969-0251
Madison MarshHarvard University, Cambridge, MA, 02138, USA.
Rimsha FarooqSchool of Public Health, Sechenov University, Moscow, Russia.

Funding

Deanship of Scientific Research at Northern Border University, Arar, KSA NBU-FFR-2025-2143-01
6 · The paper itself

Abstract

Since their inception, therapeutic or prophylactic vaccines have emerged as promising candidates for the prevention or treatment of infections and various diseases, including cancer and autoimmune disorders. In recent times, gold nanoparticles (GNPs) have acquired active roles in the field of vaccine development due to their intrinsic capacity to adjust and enhance the immune response. Due to their characteristics, GNPs can exert optimal effects as both delivery vehicles and adjuvants. Despite their significant importance in vaccinology, numerous obstacles need to be overcome before GNPs can be used in the formulations of vaccines in clinical settings. The current review summarizes the latest and successful use of gold nanoparticles as a viable method for developing a new generation of vaccines.

Indexed as

GoldMetal NanoparticlesVaccinesAnimalsDrug Delivery SystemsHumansNanovaccinesGoldNanovaccinesVaccinesAntibodyantigendrug deliverygold nanoparticlesimmunogenicityvaccines

Identifiers

PMID39838661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.